Market Overview

UPDATE: Morgan Stanley Reiterates on Allscripts Healthcare Solutions as Momentum will Continue in 2014

Related MDRX
Will Cerner Corp. (CERN) Miss Earnings Estimates?
Markets Mostly Higher As Earnings Season Continues To Impress

In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Allscripts Healthcare Solutions (NASDAQ: MDRX), and raised the price target from $20.00 to $21.00.

In the report, Morgan Stanley noted, “Allscripts is a diversified HCIT vendor for hospitals, physician practices, and other healthcare providers. New leadership has solidified the existing customer base with increased product quality, investment in R&D, and product roadmap. Leadership position in growing area of Population Health through strategic acquisition of dbMotion. Replacement of EHR systems ahead of Meaningful Use Stage 2 provides an opportunity from both legacy MDRX and implementation of dbMotion. Compelling valuation – trades at a steep discount to HCIT peers.”

Allscripts Healthcare Solutions closed on Thursday at $17.22.

Latest Ratings for MDRX

DateFirmActionFromTo
Aug 2014Credit SuisseMaintainsOutperform
Aug 2014JP MorganMaintainsOverweight
Aug 2014Raymond JamesMaintainsOutperform

View More Analyst Ratings for MDRX
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

 

Related Articles (MDRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters